Revolutionizing Medicine through Pharmacogenomics

Phone: (919) 465-0100 | pharmadx@cgix.com

RUTHERFORD, NJ and RALEIGH, NC, September 24, 2014 (GLOBE NEWSWIRE) – Cancer Genetics Inc. (Nasdaq; CGIX) (“CGI” or “the Company”), an emerging leader in DNA-based cancer diagnostics, today released an agenda for its upcoming Analyst Day, to be held Thursday, September 25 in Raleigh, North Carolina.

The event will offer updated information on the Company’s portfolio of disease-focused proprietary genomic tests, and will provide a comprehensive overview of proprietary test development plans, technology development and validation, and progress with research collaborations. The Analyst Day will focus on the Company’s tests for B-cell cancers, including chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL), and follicular lymphoma (FL), as well as the Company’s tests in kidney cancer and cervical cancer. In addition, Cancer Genetics will review recent updates related to its joint venture with Mayo Clinic, Oncospire Genomics, and the incorporation of pharmacogenomics into molecular profiling of tumor systems.

Cancer Genetics’ CEO Panna Sharma will open the event at 10 a.m. EDT. Other speakers from the Company will include Jane Houldsworth, Ph.D., Vice President of Research and Development (R&D); Banumathy Gowrishankar, Ph.D., Principal Scientist for R&D; and Scott Clark, Ph.D., Vice President of Scientific Development.

Gianrico Farrugia, M.D., director of Mayo Clinic’s Center for Individualized Medicine, will provide an update on CGI’s joint venture with Mayo Clinic, OncoSpire Genomics, with particular focus on multiple myeloma (MM).

Details for the event are as follows:

Date: Thursday, September 25, 2014

Time: 10 a.m. – 3 p.m. EDT

Location: Cancer Genetics Research Triangle Park (RTP) – 133 Southcenter Court, Suite 400, Raleigh, North Carolina 27560

Online: The live webcast will be available at http://ir.cancergenetics.com/company-and-portfolio-update.

For more information, please visit www.CancerGenetics.com, or follow Cancer Genetics on twitter @Cancer_Genetics.

About Cancer Genetics

Cancer Genetics Inc. (Nasdaq:CGIX) is an emerging leader in DNA-based cancer diagnostics, servicing some of the most prestigious medical institutions in the world. Our tests target cancers that are difficult to diagnose and predict treatment outcomes. These cancers include hematological, urogenital, and HPV-associated cancers. We also offer a comprehensive range of non-proprietary oncology-focused tests and laboratory services that provide critical genomic information to healthcare professionals, as well as biopharma and biotech companies. Our state-of-the-art reference lab is focused entirely on maintaining clinical excellence and is both CLIA certified and CAP accredited and has licensure from several states including New York State. We have established strong research collaborations with major cancer centers such as Memorial Sloan-Kettering, The Cleveland Clinic, Mayo Clinic and the National Cancer Institute.

Forward Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potential opportunities for Cancer Genetics, Inc. products and services, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to, statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, risks of cancellation of customer contracts or discontinuance of trials, risks that the transaction will not close or, if it closes, will not realize the currently anticipated benefits, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, maintenance of intellectual property rights and other risks discussed in the Company’s Form 10-K for the year ended December 31, 2013 and 10-Q for the quarter ended March 31, 2014 along with other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics disclaims any obligation to update these forward-looking statements.

CONTACT:

Media Relations
Paul Kuntz
RedChip Companies, Inc.
800-733-2447, ext. 105
paul@redchip.com

Investor Relations
Michael Rice
LifeSci Advisors, LLC
646-597-6997

 

> Study will correlate genetic markers to outcome in ~200 patients with diffuse large B-cell lymphoma (DLBCL), the most common form of non-Hodgkin lymphoma.

> Additional genetic markers validated in the study will be incorporated into CGI’s proprietary test and genetic signature for the prediction of outcome in DLBCL.

RUTHERFORD, N.J., September 23, 2014 – Cancer Genetics, Inc. (Nasdaq; CGIX) (“CGI” or “The Company”), an emerging leader in DNA-based cancer diagnostics, and Beth Israel Deaconess Medical Center, announced today that they have entered into a collaboration to examine genomic biomarkers in patients with Diffuse Large B-Cell Lymphoma (DLBCL), and use an integrated approach to investigate their association with patient outcome.

Approximately 200 DLBCL tumors from patients previously treated with current frontline immunotherapeutic regimens (eg., Rituximab) will be evaluated. The biomarkers assessed will include genomic rearrangements, copy number changes, and mutations. Copy number changes will be detected by CGI’s proprietary MatBA® array, which is commercially available as a laboratory developed test and is CLIA and NYS approved. Mutation analysis of a panel of genes known to be altered in DLBCL will be performed by next-generation sequencing (NGS). By looking at these patient samples and assessing the relationship of shared genetic variants to overall survival, the study will allow researchers to assess the genomic landscape of DLBCL tumors and integrate knowledge of shared genomic alterations into a robust, clinically validated model of DLBCL patient survival and outcome. Genomic variants with prognostic value validated in prior studies performed by CGI and in this collaboration will be integrated into CGI’s CompleteSM program for DLBCL, offering improved value for patients, doctors, and the biopharma community.

“CGI’s collaboration with Beth Israel Deaconess Medical Center reiterates our commitment to providing best-in-class prognostic and diagnostic tests for hematological cancers. We recognize the significant ongoing need for genomic prognostic markers in these cancers, in particular DLBCL, and are proud to be at the forefront of personalized medicine for hematological oncology,” said Panna Sharma, CEO of Cancer Genetics, Inc.

DLBCL is the most common type of aggressive non-Hodgkin Lymphoma, accounting for approximately 40% of all B-cell malignancies.  An estimated 190,000 people in the United States are currently living with, or are in remission from, DLBCL, and approximately 20,000 new cases are diagnosed each year. Prognosis and outcome prediction for these patients is difficult, and is currently based primarily on clinical features and few molecular markers. To date, a number of studies have reported the relationship of individual molecular markers to prognosis, but the relationship of these individual markers to one another has not been adequately examined or built into a comprehensive model. The collaboration between Cancer Genetics and Beth Israel Deaconess Medical Center will allow researchers to determine the relationship of these genomic biomarkers to one another and their collective impact on DLBCL patient overall survival.

The addition of robust molecular markers to assist in predicting patient outcome will improve patient stratification and prognostication in DLBCL, and will better identify those patients likely to have an overall good prognosis, versus those who are likely to relapse or who are not likely to respond to treatment.  Improved DLBCL prognostication will allow clinicians to implement more personalized, risk-adapted treatment options for their patients, and better inform patient monitoring.

The company’s collaboration with Beth Israel Deaconess Medical Center is one of a number of research partnerships in which the company is currently engaged. Cancer Genetics, Inc. believes that their improved proprietary diagnostic and prognostic panels will continue to prove beneficial for cancer patients, as well as clinical trial customers and sponsors. A number of advancements in the treatment of hematological cancers have recently been made, and there are currently more than 1500 clinical trials in phase II and III for B-cell malignancies. As the number of these trials continues to increase, CGI expects an increasing demand for their proprietary MatBA® test for B-cell neoplasms.

About Beth Israel Deaconess Medical Center

Beth Israel Deaconess Medical Center is a patient care, teaching and research affiliate of Harvard Medical School, and currently ranks third in National Institutes of Health funding among independent hospitals nationwide.

BIDMC is in the community with Beth Israel Deaconess Hospital-Milton, Beth Israel Deaconess Hospital-Needham, Beth Israel Deaconess Hospital-Plymouth, Anna Jaques Hospital, Cambridge Health Alliance, Lawrence General Hospital, Signature Health Care, Beth Israel Deaconess HealthCare, Community Care Alliance, and Atrius Health. BIDMC is also clinically affiliated with the Joslin Diabetes Center and Hebrew Senior Life and is a research partner of Dana-Farber/Harvard Cancer Center. BIDMC is the official hospital of the Boston Red Sox. For more information, visit www.bidmc.org.

About Cancer Genetics

Cancer Genetics Inc. (Nasdaq:CGIX) is an emerging leader in DNA-based cancer diagnostics, servicing some of the most prestigious medical institutions in the world. Our tests target cancers that are difficult to diagnose and predict treatment outcomes. These cancers include hematological, urogenital, and HPV-associated cancers. We also offer a comprehensive range of non-proprietary oncology-focused tests and laboratory services that provide critical genomic information to healthcare professionals, as well as biopharma and biotech companies. Our state-of-the-art reference lab is focused entirely on maintaining clinical excellence and is both CLIA certified and CAP accredited and has licensure from several states including New York State. We have established strong research collaborations with major cancer centers such as Memorial Sloan-Kettering, The Cleveland Clinic, Mayo Clinic and the National Cancer Institute.

For more information, please visit www.CancerGenetics.com, or follow Cancer Genetics on twitter @Cancer_Genetics.

Forward Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potential opportunities for Cancer Genetics, Inc. products and services, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to, statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, risks of cancellation of customer contracts or discontinuance of trials, risks that the transaction will not close or, if it closes, will not realize the currently anticipated benefits, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, maintenance of intellectual property rights and other risks discussed in the Company’s Form 10-K for the year ended December 31, 2013 and 10-Q for the quarter ended March 31, 2014 along with other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics disclaims any obligation to update these forward-looking statements.

 

CONTACT:

Media Relations
Paul Kuntz
RedChip Companies, Inc.
800-733-2447, ext. 105
paul@redchip.com

Investor Relations
Michael Rice
LifeSci Advisors, LLC
646-597-6997

 

RUTHERFORD, N.J., Sept. 10, 2014 (GLOBE NEWSWIRE) – Cancer Genetics, Inc. (Nasdaq:CGIX) (“CGI” or “The Company”), an emerging leader in DNA-based cancer diagnostics, announced today that Panna Sharma will present at the Aegis Healthcare and Technology Conference on Thursday, September 11, 2014 at 8:30 am Pacific Daylight Time (11:30 am EDT).

A copy of the presentation will be available online at http://ir.cancergenetics.com/presentations.

For more information, please visit www.CancerGenetics.com, or follow Cancer Genetics on twitter @Cancer_Genetics.

About Cancer Genetics

Cancer Genetics Inc. (Nasdaq:CGIX) is an emerging leader in DNA-based cancer diagnostics, servicing some of the most prestigious medical institutions in the world. Our tests target cancers that are difficult to diagnose and predict treatment outcomes. These cancers include hematological, urogenital, and HPV-associated cancers. We also offer a comprehensive range of non-proprietary oncology-focused tests and laboratory services that provide critical genomic information to healthcare professionals, as well as biopharma and biotech companies. Our state-of-the-art reference lab is focused entirely on maintaining clinical excellence and is both CLIA certified and CAP accredited and has licensure from several states including New York State. We have established strong research collaborations with major cancer centers such as Memorial Sloan-Kettering, The Cleveland Clinic, Mayo Clinic and the National Cancer Institute.

For further information, please see http://www.cancergenetics.com.

Forward Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potential opportunities for Cancer Genetics, Inc. products and services, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to, statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, risks of cancellation of customer contracts or discontinuance of trials, risks that the transaction will not close or, if it closes, will not realize the currently anticipated benefits, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, maintenance of intellectual property rights and other risks discussed in the Company’s Form 10-K for the year ended December 31, 2013 and 10-Q for the quarter ended March 31, 2014 along with other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics disclaims any obligation to update these forward-looking statements.

CONTACT: Media Relations

Paul Kuntz
RedChip Companies, Inc.
800-733-2447, ext. 105
paul@redchip.com

Investor Relations
Michael Rice
LifeSci Advisors, LLC
646-597-6997

Source: Cancer Genetics, Inc.

September 11, 2014 at 8:30 am PT

Las Vegas, NV

Date: September 8 – 10, 2014
Location: Boston, MA

Date: September 8 – 10, 2014
Location: Raleigh, NC

  • Acquisition Adds Contracts With Five of the Top Biopharma Companies Globally
  • Increases Overall Biopharma Contract Backlog to Over $18 Million
  • Uniquely Positions CGI to Provide Genomic Testing Globally Including China, One of Fastest Growing Countries For Both Clinical Trials and Cancer Testing

RUTHERFORD, N.J., July 21, 2014 (GLOBE NEWSWIRE) — Cancer Genetics, Inc. (Nasdaq:CGIX), an emerging leader in DNA-based cancer diagnostics focused on developing genomic-based oncology tests and services, today announced the signing of a definitive agreement to acquire privately held Gentris Corporation, a global provider of clinical pharmacogenomics solutions, next-generation sequencing, and biomarker testing.

CGI expects the acquisition to add approximately $5 to $6 million in annual sales, and add substantially to it biopharma revenue backlog and capabilities. The company will now be positioned to provide global services for genomic and biomarker testing for biotech and pharmaceutical companies by leveraging both it’s unique tests and comprehensive oncology services.

Gentris provides genomic testing and pharmacogenomics services to half of the top ten biopharma companies globally and has participated and performed genomic analysis for over 1,000 clinical trials. The company has operations in Raleigh (Research Triangle Park), North Carolina and Shanghai, China in state-of-the-art GLP, CLIA and FDA-compliant facilities.

Gentris’ expertise in pharmacogenomics, the study of the role of an individual’s genetics in drug response, enables its clients to quickly obtain and translate quality genomic biomarker results into safer, more effective medicines that improve and personalize the standard of care for patients globally. Gentris also adds CAP accredited biorepository and tissue management services for CGI’s growing global client base through an additional 28,000 square feet of laboratory space.

Panna Sharma, CEO of Cancer Genetics, stated: “The acquisition of Gentris will serve as a strong foundation for the expansion of our programs into the clinical and hospital setting globally. We now have fully staffed laboratories in the U.S., India and China, which gives us a uniquely competitive platform to develop, commercialize, and deliver genomic and biomarker based oncology diagnostics to our clients. Importantly, this acquisition provides a clear pathway and high growth opportunity to sell our genomic based diagnostic tests to some of the largest pharma companies in the world with additional capabilities such as germline DNA testing and drug response optimization and monitoring.”

Mr. Sharma also added: “The fact that large biopharma companies are continuing to invest heavily in China and that cancer is now the single largest cause of death in China, makes it important that CGI expand its operations and capabilities in this market. Gentris’ presence in China provides us the platform to do so.” According to Thomson-Reuters clinical intelligence service, Cortellus, 550 to 600 clinical trials are initiated in China each year with nearly forty percent focused on oncology.

With the acquisition of Gentris, and the previously announced BioServe India acquisition, Cancer Genetics will have approximately 60,000 square feet of state-of-the-art lab space and will have established itself as a unique global provider for the development and delivery of targeted, personalized oncology diagnostics.

About Cancer Genetics

Cancer Genetics, Inc. (Nasdaq:CGIX) is an emerging leader in DNA-based cancer diagnostics, servicing some of the most prestigious medical institutions in the world. Its tests target cancers that are difficult to diagnose and predict treatment outcomes. These cancers include hematological, urogenital and HPV-associated cancers. It also offers a comprehensive range of non-proprietary oncology-focused tests and laboratory services that provide critical genomic information to healthcare professionals, as well as biopharma and biotech companies. Its state-of-the-art reference lab is focused entirely on maintaining clinical excellence and is both CLIA certified and CAP accredited and has licensure from several states including New York State. It has established strong research collaborations with major cancer centers including Memorial Sloan-Kettering, The Cleveland Clinic, Mayo Clinic and the National Cancer Institute. For further information, please see www.cancergenetics.com.

Forward Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potential opportunities for Cancer Genetics, Inc. products and services, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to, statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, risks of cancellation of customer contracts or discontinuance of trials, risks that we will not reach agreement on definitive acquisition agreements with Gentris, or that the Gentris and/or BioServe transactions will not close or, if either or both closes, will not realize the currently anticipated benefits, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, maintenance of intellectual property rights and other risks discussed in the Company’s Form 10-K for the year ended December 31, 2013 and 10-Q for the quarter ended March 31, 2014 along with other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics disclaims any obligation to update these forward-looking statements.

CONTACT:

Investor Relations:
Andrew McDonald LifeSci Advisors, LLC
646-597-6987

Public Relations:
John Cunningham RedChip Companies, Inc.
800-733-2447 x 105

Source: Cancer Genetics, Inc.

In keeping with the Gentris mission to promote excellence in pharmacogenomics testing, Gentris members are actively engaged in pharmacogenomic research with academic partners.

Scott Clark, VP of Global Scientific Operations at Gentris, and colleagues from the University of North Carolina at Chapel Hill, North Carolina State University, University of Michigan, Lineberger Comprehensive Cancer Center and the Moffitt Cancer Center recently published their results which examined the association of genetic variants with peripheral neuropathy in breast cancer patients treated with paclitaxel.

Paclitaxel is commonly used to treat breast tumors. It is understood that levels of toxicity differ significantly among patients and is dependent on drug exposure and genetics. In addition, the risk of developing sensory peripheral neuropathy is elevated in African-American patients. (more…)

Read the Article:
HCV Status and Other Pre-analytical Variables Influence DNA Yield from Whole Blood

Read the Article:
The Impact of Storage Conditions on DNA Derived from Buccal Swabs


Our Services

At Gentris, we believe in providing the highest level of quality services to meet our customer’s needs. From our CAP Accredited biorepository, to our CLIA regulated laboratory, we strive to be the leader in pharmacogenomics solutions.